DBG
VRTX icon

De Burlo Group’s Vertex Pharmaceuticals VRTX Stock Holding History

De Burlo Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.12M Sell
4,755
-30
-0.6% -$14K 0.48% 44
2025
Q4 		$2.17M Sell
4,785
-240
-5% -$103K 0.26% 44
2025
Q3 		$1.97M Sell
5,025
-43,740
-90% -$18.3M 0.24% 48
2025
Q2 		$21.7M Buy
48,765
+30
+0.1% +$13.8K 2.86% 13
2025
Q1 		$23.6M Hold
48,735
– – 3.49% 8
2024
Q4 		$19.6M Sell
48,735
-460
-0.9% -$213K 2.62% 15
2024
Q3 		$22.9M Buy
49,195
+630
+1% +$303K 2.82% 12
2024
Q2 		$22.8M Buy
48,565
+8,525
+21% +$3.7M 3.06% 14
2024
Q1 		$16.7M Sell
40,040
-24,725
-38% -$10.5M 2.22% 21
2023
Q4 		$22.5M Hold
64,765
– – 3.91% 9
2023
Q3 		$22.5M Buy
64,765
+715
+1% +$250K 3.91% 9
2023
Q2 		$22.5M Buy
64,050
+8,310
+15% +$2.8M 3.75% 6
2023
Q1 		$17.6M Hold
55,740
– – 3.43% 6
2022
Q4 		$16.1M Sell
55,740
-6,680
-11% -$2.04M 3.6% 9
2022
Q3 		$18.1M Buy
+62,420
New +$18M 4.3% 5
2022
Q2 		– Sell
-68,410
Closed -$17.9M – 195
2022
Q1 		$17.9M Buy
+68,410
New +$16.2M 3.32% 10
2020
Q4 		– Sell
-810
Closed -$220K – 96
2020
Q3 		$220K Sell
810
-74,110
-99% -$20.4M 0.04% 81
2020
Q2 		$17.8M Hold
74,920
– – 5% 4
2020
Q1 		$17.8M Buy
74,920
+920
+1% +$211K 5% 4
2019
Q4 		$16.2M Buy
+74,000
New +$15M 3.27% 8
2018
Q2 		– Sell
-44,800
Closed -$7.3M – 118
2018
Q1 		$7.3M Buy
44,800
+26,900
+150% +$4.39M 1.59% 24
2017
Q4 		$2.68M Sell
17,900
-17,700
-50% -$2.62M 0.54% 52
2017
Q3 		$5.41M Buy
+35,600
New +$5.36M 1.2% 31

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

De Burlo Group's VRTX Position: Q1 2026 in Review

De Burlo Group reduced its Vertex Pharmaceuticals (VRTX) stake by 0.63% in Q1 2026, selling an estimated $14K and leaving 4,755 shares worth $2.12M. The position accounts for 0.48% of the portfolio, ranked #44.

De Burlo Group first reported a position in VRTX in Q3 2017 and has held it in 23 quarters since. The position peaked at $23.6M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • De Burlo Group held 4,755 shares of Vertex Pharmaceuticals worth $2.12M as of Q1 2026.
  • De Burlo Group sold 30 Vertex Pharmaceuticals shares in Q1 2026, an estimated $14K.
  • Vertex Pharmaceuticals made up 0.48% of De Burlo Group's portfolio in Q1 2026, its #44 holding.
  • De Burlo Group first reported a position in Vertex Pharmaceuticals in Q3 2017 and has held it in 23 quarters since.
  • De Burlo Group's Vertex Pharmaceuticals position peaked at $23.6M in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on De Burlo Group's 13F filing for Q1 2026, filed 14 May 2026.